drugset / Trial / NCT00000936
A Study To Test An Anti-Rejection Therapy After Kidney Transplantation
RandomizedParallel-groupDouble-blindTreatment
Summary
Kidney transplantation is often successful. However, despite aggressive anti-rejection drug therapy, some patients will reject their new kidney. This study is designed to test two anti-rejection approaches. Two medications in this study are currently used in children, but there is no information regarding which drug is safer or more effective. Survival rates in renal transplantation are unacceptably low. Therefore, there is a need for an improved post-transplant treatment, such as the induction therapy used in this study.
Timeline
- Start
- 1999-11
- Primary completion
- —
- Completion
- 2004-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cyclosporine | Peptide | 15 mg/kg | Oral |
| Subject | Cyclosporine | Peptide | 500 mg/m2 | Oral |
| Subject | hOKT3 | Unknown | 2.5 mg | Intravenous |
| Subject | hOKT3 | Unknown | 5 mg | Intravenous |
Indications
No indication recorded.